Horizon scanning: Phase II study of MEK162 for advanced melanoma harbouring NRAS or Val600 BRAF mutations
Source: Lancet Oncology
Area: News
An open-label, non-randomised, phase II study has reported positive data for MEK162 targeted therapy in patients with NRAS -mutated melanoma.
A total of 71 patients with NRAS-mutated (n=30) or BRAF-mutated (n=41) advanced melanoma enrolled at cancer centres in Europe and the USA were assigned to the following three arms:
. twice-daily MEK162 45 mg for NRAS-mutated melanoma,
. twice-daily MEK162 45 mg for BRAF-mutated melanoma,
. twice-daily MEK162 60 mg for BRAF-mutated melanoma.
The primary endpoint was the proportion of patients who had an objective response (ie, a complete response or confirmed partial response).
At median follow-up of 3.3 months, the following data were reported for the 45mg groups only:
. Six (20%) of 30 patients with NRAS-mutated melanoma had a partial response (three confirmed) as did eight (20%) of 41 patients with BRAF-mutated melanoma (two ...
Source: NeLM - News - Category: Drugs & Pharmacology Source Type: news
More News: Cancer | Cancer & Oncology | Drugs & Pharmacology | Melanoma | PET Scan | Skin Cancer | Study